Événement thromboembolique et hyperhomocystéinémie métabolique : case-report et revue de la littérature

Biron, F.; Rousseau, J; Baulin, J.-M.; Guérin-Boyer, M.; Lanéelle, Damien

doi:10.1016/j.ancard.2021.01.008

Annales de Cardiologie et d'Angéiologie

2021

DOI: 10.1016/j.ancard.2021.01.008

|View full text |Cite

Événement thromboembolique et hyperhomocystéinémie métabolique : case-report et revue de la littérature

F. Biron¹,

J Rousseau²,

J.-M. Baulin³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Homocysteine, cancer and oncothrombosis

Bitsadze,

Slukhanchuk,

Solopova

et al. 2023

Akušerstvo, ginekologiâ i reprodukciâ

View full text Add to dashboard Cite

Introduction. Hyperhomocysteinemia (HHC) is one of the arms in the pathogenesis of thrombotic complications in female cancer patients.Aim: to assess an HHC-related impact to developing thrombotic complications in patients with malignant neoplasms of the female genital organs and breast cancer.Materials and Methods. There were retrospectively evaluated the data collected from 236 patients: with ovarian tumors (n = 63), cervical cancer (n = 51), breast tumors (n = 64), malignant neoplasms of the uterine body (n = 58). The control group consisted of 50 women without malignant neoplasms. The analysis of homocysteine (HC) concentration, the frequency of polymorphisms of the genes encoding folate cycle enzymes MTHFR C677T, MTHFR A1298C, MTRR A66G, MTR A2756G as well as the rate of thrombotic complications was carried out. A risk of blood HC level-related thrombotic complications was assessed.Results. Plasma HC concentration comprised ≥ 22 μmol/l in 30.5 % of patients. Thrombotic complications within one year after discharge from the hospital were developed in 15.3 % cases. The risk of thrombotic complications turned out to be higher in patients with elevated plasma HC level (≥ 22 μmol/l) (odds ratio = 2.99; 95 % confidence interval = 1.11–8.08). No significantly increased prevalence of polymorphisms in the genes encoding folate cycle enzymes among female cancer patients was detected.Conclusion. Monitoring HC level in female cancer patients contributes separately to predict a likelihood of thrombotic complications. Prescribing drugs that reduce HC level (folic acid) and monitoring its concentration in female cancer patients during therapy, including chemotherapy, can potentially lower an incidence of thrombotic complications.

show abstract

Homocysteine, cancer and oncothrombosis

Bitsadze,

Slukhanchuk,

Solopova

et al. 2023

Akušerstvo, ginekologiâ i reprodukciâ

View full text Add to dashboard Cite

show abstract

The association of serum folate and homocysteine on venous thromboembolism in patients with colorectal cancer: a cross-sectional study

Cao¹,

Tian²,

Chen³

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background Venous thromboembolism is a common complication in patients with colorectal cancer who exhibit high homocysteine and low folate levels. However, whether venous thrombosis is the result of a direct effect of folic acid or the presence of a homocysteine-mediated mediating effect cannot be determined. This study aimed to explore the association and mediating effects of serum folate and homocysteine on venous thromboembolism in patients with colorectal cancer. Methods This study included patients with colorectal cancer who were admitted to the First Hospital of Shanxi Medical University from May 2020 to May 2022. The patients’ medical records were reviewed to collect information on general demographic characteristics, the prevalence of venous thromboembolism on admission, laboratory blood indices, serum folate, and serum homocysteine. SPSS 26.0 software was used for data collation and statistical analysis; the χ 2 test was utilized for univariate analysis and unconditional logistic regression was applied for multivariate analysis. R 4.1.2 was used to perform the mediating effect test. Results A total of 236 colorectal cancer patients were investigated. The prevalence of colorectal cancer combined with venous thromboembolism was 15.3%; serum folate was <10.75 nmol/L in 25.4% of patients; and serum homocysteine was ≥22 µmol/L in 30.5% of patients. After controlling for confounding factors, the risk of venous thromboembolism was 2.48 times greater [95% confidence interval (CI): 1.04 to 5.94] in patients with low serum folate (<10.75 nmol/L) than in those with high serum folate (≥10.75 nmol/L). Also, the risk of venous thromboembolism was greater in those with high serum homocysteine (≥22 µmol/L) [odds ratio (OR) =2.99. 95% CI: 1.11 to 8.08]. The mediating effect test showed no direct effect of serum folate on venous thromboembolism combined with colorectal cancer, and a full mediating effect of serum homocysteine between serum folate and venous thromboembolism combined with colorectal cancer, with a mediating effect value of 0.002 and a total effect value of 0.0054. Conclusions Serum folate influences the formation of venous thromboembolism through serum homocysteine. It is recommended that the nutritional supplementation of patients be enhanced to control serum folate and serum homocysteine levels.

show abstract

A Case of Vitamin B12 Deficiency and Hyperhomocysteinemia-induced Sub-massive Pulmonary Thromboembolism

Kumar,

Kanjilal,

Roy

et al. 2024

Bengal Physician Journal

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Événement thromboembolique et hyperhomocystéinémie métabolique : case-report et revue de la littérature

Cited by 3 publications

References 18 publications

Homocysteine, cancer and oncothrombosis

Homocysteine, cancer and oncothrombosis

The association of serum folate and homocysteine on venous thromboembolism in patients with colorectal cancer: a cross-sectional study

A Case of Vitamin B12 Deficiency and Hyperhomocysteinemia-induced Sub-massive Pulmonary Thromboembolism

Contact Info

Product

Resources

About